Epygen Biotech

Mumbai, India Founded: 2016 • Age: 10 yrs
Therapeutic proteins for oncology and cardiovascular disorders are developed.
Annual revenue $911,350 Latest available
Total funding - Funding intelligence
Employees 47 Tracked headcount
Investors - Known backers
Products 6 Services tracked
Competitors - Brand Intelligence

About Epygen Biotech

Epygen Biotech is a company based in Mumbai (India) founded in 2016. The company has 47 employees as of April 08, 2024. Epygen Biotech offers products and services including Recombinant Streptokinase, Pegfilgrastim, Bevacizumab, Teriparatide, and SARS-CoV-2 Vaccine.

  • Headquarter Mumbai, India
  • Employees 47 as on 08 Apr, 2024
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Epygen Biotech Private Limited
  • Date of Incorporation 25 Aug, 2011
  • Jurisdiction Rasayani, Maharashtra, India
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $911.35 K (USD)
    179.47
    as on Mar 31, 2023
  • Net Profit
    -$200.41 K (USD)
    66.14
    as on Mar 31, 2023
  • EBITDA
    $345.65 K (USD)
    135.77
    as on Mar 31, 2023
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    47

    as on Apr 08, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Epygen Biotech

Epygen Biotech offers a comprehensive portfolio of products and services, including Recombinant Streptokinase, Pegfilgrastim, Bevacizumab, Teriparatide, and SARS-CoV-2 Vaccine.

Product name locked
Category locked
Primary

Treats cardiovascular conditions using recombinant technology.

Product name locked
Category locked
Locked

Supports oncology patients by boosting white blood cell production.

Product name locked
Category locked
Locked

Targets tumors for oncology treatment applications.

Product name locked
Category locked
Locked

Manages hormonal disorders through protein-based therapy.

Product name locked
Category locked
Locked

Provides immunity against viral infections like COVID-19.

Product name locked
Category locked
Locked

Offers contract development for biopharmaceutical production needs.

Funding Insights of Epygen Biotech

Premium access

Detailed funding history for Epygen Biotech

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Epygen Biotech

Investments
Premium access

Investment portfolio details for Epygen Biotech

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Epygen Biotech

Premium access

Detailed financials for Epygen Biotech

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Epygen Biotech Comparisons

Epygen Biotech Primary company
Description
Therapeutic proteins for oncology and cardiovascular disorde...
Location
Mumbai, India
Founded Year
2016
Annual Revenue
$911.35 K (USD)
Net Profit
-$200.41 K (USD)
EBITDA
$345.65 K (USD)
Employees
47
As of 2024
Premium access

Peer comparison for Epygen Biotech

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Epygen Biotech

Premium access

Detailed competitors of Epygen Biotech

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Epygen Biotech

Premium access

Complete news archive for Epygen Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Epygen Biotech

Epygen Biotech was founded in 2016.

Epygen Biotech is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

As of Apr 08, 2024, the latest employee count at Epygen Biotech is 47.

Annual revenue of Epygen Biotech is $911.35K as on Mar 31, 2023.

Epygen Biotech was founded in 2016 in Mumbai, India, within the biotechnology sector. Recombinant enzymes, antibodies, and hormones are developed by the company for oncology, cardiovascular, and immune disorders. The lead candidate, recombinant streptokinase, is targeted at cardiovascular conditions. Additional candidates, such as Peg-filgrastim and Bevacizumab, address cancer treatment, while teriparatide is intended for osteoporosis in postmenopausal women. Operations focus on therapeutic protein development.

Epygen Biotech offers Recombinant Streptokinase, Pegfilgrastim, Bevacizumab, Teriparatide, and 2 more products and services.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available